New innovative technology platform has creating the next generation of DNA or RNA vaccines based on the genetic code of the pathogenic agents. Drug delivery systems are come up with technologies for the targeted delivery and/or controlled release of therapeutic agents. Drugs have long been used to upgrade health condition and increase lives. Technological advances in immunology, protein design, and genetic delivery have unlocked new possibilities for vaccine concepts and delivery technology that were previously inaccessible. The most important requirements are a vaccine should be safe and efficacious can be restated as a formulation that it is made with the appropriate potency that persists over the duration of conditions until it is administered to the patient.
Stefan Gluck
Vice President, Global Medical Affairs at Celgene Corporation, United States
Hemanta Kumar Kar
Kalinga Institute of Medical Sciences(KIMS), India
Sudhakar Bangera
Fellow-vaccinology managing partner AILEEN clinical research services AILEEN, India
Mayra Ramos Suzarte
Center of Molecular Immunology, Cuba
Sushmita Koley
Senior Scientist Bio-Rad Laboratories, United States
Joe Smyser
The Public Good Projects, United States
Paul Van Buynder
Griffith University, Australia
Daniel Becker
KyooBe Tech GmbH, Germany
Patricia Canteri de Souza
State University of Londrina, BrazilSubmit your abstract Today
Title : Vaccines and monoclonal antibodies in the prolonged treatment of non-small cell lung cancer: 20 years of follow-up
Mayra Ramos Suzarte, Center of Molecular Immunology, Cuba
Title : Observational study post emergency use authorization of itolizumab in the treatment of COVID-19
Mayra Ramos Suzarte, Center of Molecular Immunology, Cuba
Title : Vaccine for AML: 2023 and beyond
Stefan Gluck, Vice President, Global Medical Affairs at Celgene Corporation, United States
Title : Purification process development of COVID antigens to identify sera needed for plasma therapy
Sushmita Koley, Senior Scientist Bio-Rad Laboratories, United States
Title : Lessons that can be learned from the rollout of the COVID-19 vaccine and the acceptance of vaccination from healthcare professionals, frontline workers and patients that need to be considered in developing a vaccine
Regina Au, BioMarketing Insight, United States
Title : Lessons learned for the future of social listening to address vaccine misinformation
Joe Smyser, The Public Good Projects, United States
Title : Why Low-Energy-Electron Irradiation might be a potential game changer for vaccine development, manufacturing, and pandemics prevention
Daniel Becker, KyooBe Tech GmbH, Germany
Title : National immunization management system- NIMS
Kashif Zulfiqar, Project Manager - NADRA, Pakistan
Title : Medicinal synthetic aluminum-magnesium silicate {Al4 (SiO4)3 + 3Mg2SiO4?2Al2 Mg3 (SiO4)3} effective for: Viral diseases; Tumors; Antimicrobial resistant infections
Maduike Chiehiura Onwubiko Ezeibe, Michael Okpara University of Agriculture, Nigeria
Title : Moving the needle for covid-19 vaccinations in Nigeria through leadership, accountability, and transparency
Fejiro Chinye Nwoko, Nigeria Solidarity Support Fund, Nigeria